Lomustine and Intermediate Dose Cytarabine in Older Patients With AML

Summary

A multicenter randomized trial was performed comparing induction therapy (IC: Idarubicin and Cytarabine, 5+7) to ICL (the same drugs plus lomustine (CCNU), 200mg\\m2 orally at day 1). Patients in complete remission (CR) were then randomized to receive either maintenance therapy or intensification with intermediate-dose cytarabine and idarubicin followed by maintenance therapy.

Timeline

Start

1995-07

Primary completion

—

Completion

2007-05

Drugs

Indications